MetaCap

Aquestive Therapeutics (AQST) vs Arvinas (ARVN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aquestive Therapeutics (AQST) has outperformed Arvinas (ARVN) over the past year, losing 39.5% versus a loss of 43.9%. Over five years, AQST leads with a -45.7% price change compared with -91.8% for ARVN. Aquestive Therapeutics is the larger company by market cap ($434.9 million vs $423.0 million), about 1.0 times the size, while Arvinas is growing revenue faster (-0.3% vs -22.6%).

Arvinas converts more of its revenue into profit, with a net margin of -30.8% versus -188.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AQST-39.51%ARVN-43.92%
+23%-14%-52%
Nov 21, 20251 yearNov 20, 2026
AQST-42.04%ARVN-92.22%
+24%-37%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AQST versus ARVN key metrics
MetricAQSTARVN
Share price$3.46$6.46
Market cap$434.88M$423.03M
1-day change-6.61%-4.15%
YTD return-46.44%-45.53%
1-year return-39.51%-43.92%
5-year return-45.68%-91.75%
EPS (TTM)$-0.65$-0.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$44.55M$262.60M
Revenue growth (YoY)-22.61%-0.30%
Net income (latest FY)$-83.78M$-80.80M
Gross margin58.35%—
Operating margin-159.50%-45.13%
Net margin-188.09%-30.77%
52-week high$6.74$14.51
52-week low$2.93$6.33
Distance from 52-week high-48.63%-55.48%
Analyst consensusstrong_buybuy
Avg. price target upside+169.65%+116.72%
Average volume2.41M848.52K
Shares outstanding125.69M65.49M
Employees147246
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Arvinas is more profitable, keeping -30.8 cents of every revenue dollar as net income versus -188.1 cents for Aquestive Therapeutics.
  • Arvinas grew revenue faster in its latest fiscal year (-0.30% vs -22.61%).

About Aquestive Therapeutics

AQST stock →

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 147 employees

About Arvinas

ARVN stock →

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees

AQST vs ARVN FAQ

Which is bigger, Aquestive Therapeutics or Arvinas?

Aquestive Therapeutics (AQST) is larger, with a market capitalization of $434.88M compared with $423.03M for Arvinas (ARVN).

Which stock has performed better over the past year, AQST or ARVN?

AQST returned -39.51% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.

Are Aquestive Therapeutics and Arvinas in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons